Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: Results from a clinical trial with a 52-week open-label extension (OLE)

Current Medical Research and Opinion

Volumn 27, Issue 8, 2011, Pages 1603-1611

  Kozma, Chris M ^a   Slaton, Terra ^a   Dirani, Riad ^b   Fastenau, John ^b   Gopal, Srihari ^c   Hough, David ^c  

^a Independent Consultant   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Clinical trial; Economic analysis; Hospitalization; Paliperidone palmitate

Indexed keywords

PALIPERIDONE; PLACEBO;

ADULT; AGE; AGED; AKATHISIA; ARTICLE; BLINDNESS; COMPARATIVE STUDY; CONTROLLED STUDY; COST; DENSITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG USE; EMERGENCY WARD; EXPOSURE; FEMALE; GENDER; HOSPITAL CHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; POPULATION; PSEUDOPARKINSONISM; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOPHRENIA; STANDARD; STATISTICAL SIGNIFICANCE; UNITED STATES;

ADULT; DOUBLE-BLIND METHOD; EMERGENCY MEDICAL SERVICES; FEMALE; HOSPITALIZATION; HUMANS; ISOXAZOLES; MALE; PALMITATES; SCHIZOPHRENIA; TIME FACTORS;

EID: 79960433520     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.595000     Document Type: Article

References (31)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised, 4th edn. Washington, DC: American Psychiatric Association, 2000.
2. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd edn. Arlington, VA: American Psychiatric Association, 2004.
3. Sharma T, Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003; 26:25-40. (Pubitemid 36384346)
4. Schizophrenia 12 month prevalence. Mental Health Information. National Institute of Mental Health. Bethesda, MD: Available at www.nimh.nih.gov/ statistics/1SCHIZ.shtml.
5. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia-. 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205.
6. Wu EQ, Birnbaum HG, Shi I, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9. (Pubitemid 41442278)
7. Malla AK, Norman RM, Voruganti LP. Improving outcome in schizophrenia: the case for early intervention. CMAJ 1999;160:843-6. (Pubitemid 29154463)
8. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med 2011;123:153-62.
9. Kreyenbuhl J, Slade EP, Medoff DR, et al. Time to discontinuation of first-and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res 2011 May 14 [Epub ahead of print]. doi:10.1016/j.schres.2011.04.028.
10. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2.
11. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
12. McCreadie RG, Wiles D, Grant S, et al. The Scottish first episode of schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 1989;80:597-602. (Pubitemid 20046946)
13. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs 2002;16:473-84. (Pubitemid 34729151)
14. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12. (Pubitemid 350033432)
15. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-.
16. Erratum in N Engl J Med 2010;363:1092-3.
17. Emsley R, Medori R, Koen L, et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210-3. Erratum in J Clin Psychopharmacol 2008;28:624. (Pubitemid 351419182)
18. Weiden PJ, Schooler NR, Weedon JC, et al. A randomized controlled trial of long-acting injectable respiridone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009;70:1397-406.
19. Girardi P, Serafini G, Pompili M, et al. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 2010;43:66-72.
20. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone longacting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24.
21. Macfadden W, Bossie CA, Turkoz I, et al. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol 2010;25:75-82.
22. Samtani M, Gopal S, Sliwa JK, et al. Switching to paliperidone palmitate from other antipsychotics: guidance based on pharmacokinetic modeling and simulation. New Clinical Drug Evaluation Unit Meeting, June 29-July 2, 2009; Hollywood, FL. Accessed September 28, 2009, http://208.81.106.111/ Poster%20Abstract%20Book%20Final.pdf.
23. Samtani M, Sliwa JK, Haskins JT, et al. Initiation dosing of deltoid intramuscular paliperidone palmitate in schizophrenia: pharmacokinetic rationale based on modeling and simulation. J Pharm Pract 2009;22:216-17.
24. Samtani MN. Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly formulation of an atypical antipsychotic. Clin Pharmacokinet 48:585-600.
25. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebocontrolled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010;30:235-44. Erratum in J Clin Psychopharmacol. 2010;30:364.
26. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107-17. Epub 2009 Dec 2.
27. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2010 Jul 8 [E-pub ahead of print]. doi: 10.1177/0269881110372817.
28. Agresti A. An Introduction to Categorical Data Analysis. New York: John Wiley & Sons, 1996.
29. Stokes M, Davis C, Koch G. Categorical Data Analysis Using the SAS-System, 2nd edn. Cary, NC: SAS Institute, Inc, 2000.
30. Owen, RT. Olanzapine: a review of rapid and long-acting parenteral formulations. Drugs Today (Barc) 2010;46:173-81.
31. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011 Mar 1. [Epub ahead of print]. doi: 10.1176/appi. ajp.2011.10081224